Cardiovascular Clinical Trials

750 recruitingLast updated: June 18, 2026

There are 750 actively recruiting cardiovascular clinical trials across 81 countries. Studies span Not Applicable, Phase 3, Phase 4, Phase 2, Phase 1, Early Phase 1. Top locations include Boston, Massachusetts, United States, New York, New York, United States, Seoul, South Korea. Updated daily from ClinicalTrials.gov.


Cardiovascular Trials at a Glance

750 actively recruiting trials for cardiovascular are listed on ClinicalTrialsFinder across 6 cities in 81 countries. The largest study group is Not Applicable with 298 trials, with the heaviest enrollment activity in Boston, New York, and Seoul. Lead sponsors running cardiovascular studies include National Heart, Lung, and Blood Institute (NHLBI), Chinese University of Hong Kong, and University of Alabama at Birmingham.

Browse cardiovascular trials by phase

Treatments under study

About Cardiovascular Clinical Trials

Looking for clinical trials for Cardiovascular? There are currently 30 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Cardiovascular trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Cardiovascular clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 750 trials

Recruiting
Phase 3

Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

Atherosclerotic Cardiovascular Disease (ASCVD)
Novartis Pharmaceuticals340 enrolled95 locationsNCT06813911
Recruiting
Not Applicable

Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions

Arterial Occlusive DiseasesPainCardiovascular Diseases+12 more
Teleflex1,859 enrolled1 locationNCT07258290
Recruiting

Product Surveillance Registry

Cardiac Rhythm DisordersDigestive disordersMinimally Invasive Surgical Procedures+13 more
Medtronic100,000 enrolled395 locationsNCT01524276
Recruiting
Not Applicable

Improving Veteran Referral to Cardiac Rehabilitation

Cardiovascular DiseaseCardiac Rehabilitation
VA Office of Research and Development816 enrolled3 locationsNCT07079358
Recruiting

EVOC - EVs in Obesity and Cardiometabolic Disease

Cardiovascular Diseases
Massachusetts General Hospital100 enrolled1 locationNCT06408961
Recruiting
Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers

Cardiovascular Disease
National Heart, Lung, and Blood Institute (NHLBI)64 enrolled1 locationNCT04216342
Recruiting

Human Biospecimen Procurement Protocol: Biorepository to Support Translational Research to Identify Disease Mechanism(s)

Cardiovascular DiseaseUndiagnosed Diseases
National Heart, Lung, and Blood Institute (NHLBI)10,000 enrolled1 locationNCT02543996
Recruiting

Diabetes and Heart Disease Risk in Blacks

ObesityCardiovascular DiseasesHypertension+1 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)2,000 enrolled1 locationNCT00001853
Recruiting
Not Applicable

Predictive Value of Systolic Rise Time of the Plantar Arch on the Risk of Major Adverse Limb Events (MALE) and Major Adverse Cardiovascular Events (MACE) in Peripheral Artery Disease (PAD) at Critical Ischaemia Stage

Peripheral Artery DiseaseMajor Adverse Cardiovascular EventsMajor Adverse Limb Events+2 more
Centre Hospitalier Universitaire, Amiens134 enrolled1 locationNCT06318767
Recruiting
Not Applicable

JUdicious Surveillance for Trastuzumab Induced Cardiotoxicity in the First Year

Breast CancerBreast Cancer Early Stage Breast Cancer (Stage 1-3)Cardiovascular Health+4 more
Women's College Hospital300 enrolled1 locationNCT06930521
Recruiting
Not Applicable

Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD

Cardiovascular DiseasesAtherosclerosisDyslipidemia+2 more
Yonsei University1,952 enrolled1 locationNCT07524101
Recruiting
Not Applicable

Predictive Value of Glycemic Parameters Measured With the FSL Pro iQ During ACS

Cardiovascular EventAcute Coronary SyndromeContinuous Glucose Measurement+1 more
University Hospital, Montpellier850 enrolled9 locationsNCT06014112
Recruiting
Phase 4

Statins to Prevent Cancer Associated Blood Clots

CancerVenous ThromboembolismCardiovascular Events
Brigham and Women's Hospital4,000 enrolled2 locationsNCT07303816
Recruiting

Measurements Before and After Participation in a Health Intervention Programme in Halsnaes Municipality

Chronic Obstructive Pulmonary Disease (COPD)Cardiovascular DiseaseType 2 Diabetes
Steno Diabetes Center Copenhagen194 enrolled1 locationNCT07641309
Recruiting
Phase 3

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

HypertensionHigh Risk Cardiovascular DiseaseHigh Cardiovascular Risk
Alnylam Pharmaceuticals11,000 enrolled856 locationsNCT07181109
Recruiting

Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks

HypertensionCardiovascular DiseaseAdrenal Gland Neoplasm+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)1,150 enrolled1 locationNCT03374215
Recruiting

Biomedical Research Informatics Centre for Cardiovascular Sciences (The BRICCS Study)

Cardiovascular DiseasesCardiovascular Risk Factor
University Hospitals, Leicester9,500 enrolled1 locationNCT04388943
Recruiting
Phase 2

Dietary Omega-7 Palmitoleic Acid-Rich Oil on Lipoprotein Metabolism and Satiety in Adults

Cardiovascular Disease
National Heart, Lung, and Blood Institute (NHLBI)110 enrolled1 locationNCT03372733
Recruiting
Not Applicable

Multidimensional Sleep Health Intervention for Couples

Blood PressureSleepCardiovascular Health
Columbia University50 enrolled1 locationNCT07603245
Recruiting
Phase 3

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

Cardiovascular DiseasesHypertensionDiabetes Mellitus, Type 2
Boehringer Ingelheim11,800 enrolled1155 locationsNCT07064473